266 related articles for article (PubMed ID: 15930295)
1. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
2. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
4. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
5. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
Myrthue A; Rademacher BL; Pittsenbarger J; Kutyba-Brooks B; Gantner M; Qian DZ; Beer TM
Clin Cancer Res; 2008 Jun; 14(11):3562-70. PubMed ID: 18519790
[TBL] [Abstract][Full Text] [Related]
6. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
Sanford DC; DeWille JW
Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray.
Swami S; Raghavachari N; Muller UR; Bao YP; Feldman D
Breast Cancer Res Treat; 2003 Jul; 80(1):49-62. PubMed ID: 12889598
[TBL] [Abstract][Full Text] [Related]
9. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
10. CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines.
Sivko GS; DeWille JW
J Cell Biochem; 2004 Nov; 93(4):830-43. PubMed ID: 15389879
[TBL] [Abstract][Full Text] [Related]
11. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
12. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.
Krishnan AV; Shinghal R; Raghavachari N; Brooks JD; Peehl DM; Feldman D
Prostate; 2004 May; 59(3):243-51. PubMed ID: 15042599
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.
Flanagan JN; Zheng S; Chiang KC; Kittaka A; Sakaki T; Nakabayashi S; Zhao X; Spanjaard RA; Persons KS; Mathieu JS; Holick MF; Chen TC
Anticancer Res; 2009 Sep; 29(9):3547-53. PubMed ID: 19667147
[TBL] [Abstract][Full Text] [Related]
14. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
Gavrilov V; Steiner M; Shany S
Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
[TBL] [Abstract][Full Text] [Related]
15. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of CCAAT/enhancer-binding protein-delta (c/EBPdelta) in rat androgen-dependent tissues and human prostate cancer.
Yang G; Gregory CW; Shang Q; O'Brien DA; Zhang YL
J Androl; 2001; 22(3):471-80. PubMed ID: 11330648
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog.
Berkovich L; Ben-Shabat S; Sintov AC
Anticancer Drugs; 2010 Jul; 21(6):609-18. PubMed ID: 20335794
[TBL] [Abstract][Full Text] [Related]
18. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.
Narvaez CJ; Welsh J
Endocrinology; 1997 Nov; 138(11):4690-8. PubMed ID: 9348195
[TBL] [Abstract][Full Text] [Related]
20. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.
Flores O; Burnstein KL
Endocrinology; 2010 Oct; 151(10):4654-64. PubMed ID: 20739400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]